Stella Pharma's loss widens as production-transfer costs bite, with supply fix due around January
Production-transfer costs of ¥191.8mn drove most of the rise in Stella Pharma's half-year overhead, and resumed shipments to Hainan follow a manufacturing-site approval the company expects around January 2027.